论文部分内容阅读
尽管单独使用CD4治疗人类免疫缺陷症病毒(HIV)感染的希望已经减小,但是当该受体与细菌毒素结合后则确实可杀死HIV感染细胞。美国Upjohn公司正在研制这种名为CD4-PE40的融合毒素,并在美国国立变态反应和传染病研究所资助下开始进行临床试验。美国北卡罗来纳大学等4所学校和医院参加了该制品多剂的安全性和耐受性试验。这4个中心将一共检测50例HIV阳性患者。他们的年龄必须为18岁,CD4计数<300,且肝脏酶浓度正常。使用剂量逐步增加,直至出现毒性。CD4是表面受体,
Although the hope of using CD4 alone to treat human immunodeficiency virus (HIV) infection has diminished, it does indeed kill HIV-infected cells when it is combined with bacterial toxins. Upjohn, the U.S. company, is developing the fusion toxin called CD4-PE40 and has started clinical trials funded by the National Institute of Allergy and Infectious Diseases. Four schools and hospitals, including the University of North Carolina in the United States, took multiple doses of the product for safety and tolerability testing. The four centers will test a total of 50 HIV-positive patients. Their age must be 18 years old, CD4 count <300, and liver enzyme concentration normal. The dosage is gradually increased until toxicity appears. CD4 is a surface receptor,